Platelet-Associated microRNAs as Markers of Aspirin Response and Pregnancy Outcome in Pregnancies at High-Risk for Preeclampsia

Abstract

Objective

Aspirin is recommended in high-risk pregnancies for the prevention of preeclampsia/preterm birth; it is unclear whether aspirin's antiplatelet or anti-inflammatory (or both) effects drive its efficacy, and there are no established markers of therapeutic efficacy for pregnancy-specific outcomes. MicroRNAs (miR) are noncoding posttranscriptional modifiers implicated in preeclampsia/preterm birth and platelet function. We aimed to evaluate whether selected platelet-associated miRs were associated with platelet inhibition following aspirin use and associated with perinatal outcomes.

Study Design

This is a planned secondary analysis of a cohort of high-risk singleton pregnancies taking aspirin. Participants had bloodwork done in the first trimester, preaspirin, 2 to 4 weeks after aspirin initiation (follow-up 1), and at 28 to 32 weeks of gestation (follow-up 2). We selected six platelet-associated miRs (16, 18a, 126, 155, 181a, and 223) that are also associated with preeclampsia and reported quantity as fold-change from baseline (follow-up/baseline). We evaluated with univariate analysis the relationship between miR fold-change at follow-up visits 1 and 2 with Platelet Function Assay-100 epinephrine closure time (PFA-100, Siemens), a measure of aspirin response. We also evaluated the relationship between miR fold-change from baseline at each visit and the outcome of (1) hypertensive disorders of pregnancy (HDP): preeclampsia or gestational hypertension and (2) preterm birth < 37 weeks.

Results

Of the original cohort, 57 were included in this secondary analysis. The fold-change in miR-223 and miR-18a significantly decreased with increasing PFA-100 epinephrine closure time. Twelve (21%) pregnancies had HDP, and eight (14%) had preterm birth < 37 weeks. Four preterm births were due to severe preeclampsia, and one was preeclampsia without severe features and spontaneous labor. Fold-change in miRs was not associated with HDP, but increased miR-223 at 28 to 32 weeks was significantly associated with an increased risk of preterm birth (odds ratio: 2.77 [1.21–6.87]; p = 0.04).

Conclusion

Selected platelet-associated miRs may be promising markers to assess the therapeutic effect of aspirin in pregnancy and warrant further exploration.

Key Points

• Platelet-associated miR decreases in association with platelet inhibition.

• Elevated miR-223 in the third trimester may be associated with preterm birth.

• Platelet-associated miR may be a marker of aspirin therapeutic effect in pregnancy.

Keywords

microRNA - preeclampsia - preterm birth - aspirin - pregnancy - platelet

Note

This study was presented at the Society for Maternal Fetal Medicine Annual Meeting on February 14, 2023.

Publikationsverlauf

Eingereicht: 26. Juni 2025

Angenommen: 05. August 2025

Artikel online veröffentlicht:
26. August 2025

• References

• 1 Rolnik DL, Nicolaides KH, Poon LC. Prevention of preeclampsia with aspirin. Am J Obstet Gynecol 2022; 226 (2S): S1108-S1119
• 2 Bounds KR, Chiasson VL, Pan LJ, Gupta S, Chatterjee P. MicroRNAs: new players in the pathobiology of preeclampsia. Front Cardiovasc Med 2017; 4 (September): 60
• 3 Jairajpuri DS, Malalla ZH, Mahmood N, Almawi WY. Circulating microRNA expression as predictor of preeclampsia and its severity. Gene 2017; 627: 543-548
• 4 Sheikh AM, Small HY, Currie G, Delles C. Systematic review of micro-RNA expression in pre-eclampsia identifies a number of common pathways associated with the disease. PLoS One 2016; 11 (08) e0160808
• 5 Bhati T, Ray A, Arora R, Siraj F, Parvez S, Rastogi S. Immunomodulation of cytokine signalling at feto-maternal interface by microRNA-223 and -150-5p in infection-associated spontaneous preterm birth. Mol Immunol 2023; 160: 1-11
• 6 Nagalla S, Shaw C, Kong X. et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood 2011; 117 (19) 5189-5197
• 7 Lindsay CR, Edelstein LC. MicroRNAs in platelet physiology and function. Semin Thromb Hemost 2016; 42 (03) 215-222
• 8 Sunderland N, Skroblin P, Barwari T. et al. MicroRNA biomarkers and platelet reactivity: the clot thickens. Circ Res 2017; 120 (02) 418-435
• 9 Zhang YY, Zhou X, Ji WJ. et al. Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. J Thromb Thrombolysis 2014; 38 (01) 65-72
• 10 Chyrchel B, Totoń-Żurańska J, Kruszelnicka O. et al. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: a preliminary report. Platelets 2015; 26 (06) 593-597
• 11 Tang QJ, Lei HP, Wu H. et al. Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy. Acta Pharmacol Sin 2019; 40 (02) 208-215
• 12 Tsochandaridis M, Nasca L, Toga C, Levy-Mozziconacci A. Circulating microRNAs as clinical biomarkers in the predictions of pregnancy complications. BioMed Res Int 2015; 2015: 294954
• 13 Edelstein LC, McKenzie SE, Shaw C, Holinstat MA, Kunapuli SP, Bray PF. MicroRNAs in platelet production and activation. J Thromb Haemost 2013; 11 (Suppl. 01) 340-350
• 14 Boelig RC, Foecke Munden E, Zhan T, McKenzie SE, Kraft WK. Pharmacodynamics of aspirin through gestation: predictors of aspirin response and association with pregnancy outcome, a prospective cohort study. Clin Transl Sci 2025; 18 (03) e70167
• 15 Kaudewitz D, Skroblin P, Bender LH. et al. Association of microRNAs and YRNAs with platelet function. Circ Res 2016; 118 (03) 420-432
• 16 Willeit P, Zampetaki A, Dudek K. et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 2013; 112 (04) 595-600